Imfinzi (durvalumab)

pCPA File Number: 23466

Negotiation Status:

Under consideration for negotiation

Indication(s):

In combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by adjuvant durvalumab monotherapy, for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).

Sponsor/Manufacturer:

AstraZeneca Canada Inc.

CDA-AMC Project Number:

PC0427-000

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable